Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline in symptomatic Alzheimer’s disease (AD). Although regulatory approval of this approach is still pending, preparing the healthcare system for the advent of disease-modifyin...
Alternative Titles
Full title
Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_gup_ub_gu_se_291734
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_291734
Other Identifiers
ISSN
1359-4184,1476-5578
E-ISSN
1476-5578
DOI
10.1038/s41380-020-0721-9
